Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
2.510
+0.070 (2.87%)
At close: Mar 9, 2026, 4:00 PM EDT
2.560
+0.050 (1.99%)
After-hours: Mar 9, 2026, 5:32 PM EDT
LIXT Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
21.87M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLIXT News
- 19 days ago - LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary - GlobeNewsWire
- 6 weeks ago - DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE - GlobeNewsWire
- 6 weeks ago - LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29 - GlobeNewsWire
- 2 months ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 3 months ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 3 months ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire
- 3 months ago - LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers - Accesswire
- 3 months ago - LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment - GlobeNewsWire